Type 1 diabetes – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Type 1
diabetes has traditionally been diagnosed based on clinical catabolic symptoms
suggestive of insulin deficiency: polyuria, polydipsia, weight loss, and marked
hyperglycemia that is nonresponsive to oral agents. It is categorized as an
autoimmune disease with progressive b-cell destruction, resulting in a
physiological dependence on exogenous insulin. Recent studies have broadened
our understanding of the disease but have made diagnosis more complex. Type 1
diabetes care must be an iterative process, adapted as the needs of the
individual evolve. In children and adults, clinical assessments for type 1
diabetes should incorporate age-appropriate and complication-focused evaluations
based on the possibility that an abnormality will be present. A young adult
with common cardiovascular disease (CVD) risk and no complications may need
more assessment of lifestyle adjustment than an older adult with a long time of
the disease who may need more vascular and neurological issues evaluation.
The
prevalence rate of Type 1 diabetes varies from 0.06% to 0.1% among all the
population in the USA
The competitive
landscape of Type 1 diabetes includes country-specific approved and pipeline
therapies. Any asset/product-specific designation or review and Accelerated
Approval are tracked and supplemented with analyst commentary.
KOLs insights of Type 1
diabetes across 8 MM market from the center of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Type 1
diabetes Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 Teplizumab MacoGenics Phase 3
2 IMT-002 Immunomolecular Therapeutics, Inc. Phase 1
3 ORMD-0801 Oramed, Ltd. Phase 2
4 Dapagliflozin AstraZeneca Phase 3
5 Albiglutide GlaxoSmithKline Phase
2
6 Humalog Halozyme Therapeutics Phase
2
7 Sotagliflozin Lexicon Pharmaceuticals Phase
2
8 ADO09 Adocia Phase 2
9 Alpha-1 Antitrypsin Kamada, Ltd. Phase 2
10 IMCY-0098 Imcyse SA Phase 2
Continued
Comments
Post a Comment